Division of Cardiology, Department of Medicine, University of California-San Francisco (Fresno-MEP), Fresno, CA 93701, USA.
Med Clin North Am. 2012 Sep;96(5):987-1000. doi: 10.1016/j.mcna.2012.07.007. Epub 2012 Aug 17.
Heart failure (HF) and atrial fibrillation (AF) are highly prevalent debilitating conditions that often coexist and are frequently encountered in clinical practice. The presence of chronic AF is a marker of worse prognosis in patients with HF, and the onset of new AF in those with chronic HF is associated with increased morbidity and mortality. Advances in the development of novel drugs, nonpharmacologic modalities, and therapeutic strategies, as well the increased understanding of the pathobiology of HF and AF, are key to mitigating the tremendous public health burden that is associated with these conditions.
心力衰竭（HF）和心房颤动（AF）是两种高发的使人虚弱的疾病，常同时存在，并在临床实践中经常遇到。慢性 AF 的存在是 HF 患者预后较差的标志，而在慢性 HF 患者中出现新的 AF 与发病率和死亡率的增加有关。新型药物、非药物治疗方法和治疗策略的发展进步，以及对 HF 和 AF 的病理生理学的深入理解，是减轻这些疾病带来的巨大公共卫生负担的关键。
